DE69620233T2 - Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren - Google Patents

Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren

Info

Publication number
DE69620233T2
DE69620233T2 DE69620233T DE69620233T DE69620233T2 DE 69620233 T2 DE69620233 T2 DE 69620233T2 DE 69620233 T DE69620233 T DE 69620233T DE 69620233 T DE69620233 T DE 69620233T DE 69620233 T2 DE69620233 T2 DE 69620233T2
Authority
DE
Germany
Prior art keywords
oxidized glutathione
glutathione
pharmaceutically acceptable
gssg
oxidized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69620233T
Other languages
German (de)
English (en)
Other versions
DE69620233D1 (de
Inventor
Mark Borisovich Balazovsky
Leonid Andreevich Kozhemyakin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectar Biosciences Inc
Original Assignee
Novelos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU95120403/14A external-priority patent/RU2089179C1/ru
Application filed by Novelos Therapeutics Inc filed Critical Novelos Therapeutics Inc
Publication of DE69620233D1 publication Critical patent/DE69620233D1/de
Application granted granted Critical
Publication of DE69620233T2 publication Critical patent/DE69620233T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
DE69620233T 1995-12-14 1996-12-10 Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren Expired - Lifetime DE69620233T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU95120403/14A RU2089179C1 (ru) 1995-12-14 1995-12-14 Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
PCT/RU1996/000226 WO1997021443A1 (en) 1995-12-14 1996-08-08 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
PCT/RU1996/000340 WO1997021444A1 (en) 1995-12-14 1996-12-10 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof

Publications (2)

Publication Number Publication Date
DE69620233D1 DE69620233D1 (de) 2002-05-02
DE69620233T2 true DE69620233T2 (de) 2002-11-14

Family

ID=26653679

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620233T Expired - Lifetime DE69620233T2 (de) 1995-12-14 1996-12-10 Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren

Country Status (8)

Country Link
EP (1) EP0869809B1 (cg-RX-API-DMAC7.html)
JP (2) JP2000515111A (cg-RX-API-DMAC7.html)
AT (1) ATE214936T1 (cg-RX-API-DMAC7.html)
AU (1) AU1113097A (cg-RX-API-DMAC7.html)
CA (1) CA2239874A1 (cg-RX-API-DMAC7.html)
DE (1) DE69620233T2 (cg-RX-API-DMAC7.html)
ES (1) ES2174124T3 (cg-RX-API-DMAC7.html)
WO (1) WO1997021444A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU746946B2 (en) * 1997-03-21 2002-05-09 Shiseido Company Ltd. Immunopotentiators
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
JP2002509715A (ja) * 1998-03-30 2002-04-02 イ・デ・エム・イミュノ−デジネ・モレキュル 刺激された単球に由来する細胞、その調製及び用途
JP2000169371A (ja) * 1998-10-02 2000-06-20 Sankyo Co Ltd ジチオラン誘導体を含有する医薬
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US20070142267A1 (en) 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2229892C2 (ru) * 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких
US7173013B2 (en) 2001-06-08 2007-02-06 Sciclone Pharmaceuticals, Inc. Treatment of tuberculosis using immunomodulator compounds
EP1596756A4 (en) * 2003-01-23 2009-11-11 Supernus Pharmaceuticals Inc MEANS TO INCREASE ABSORPTION
RU2482868C1 (ru) * 2011-12-30 2013-05-27 Общество С Ограниченной Ответственностью "Ива Фарм" Средство для лечения диабета, фармацевтическая композиция и способ лечения заболеваний
ES2659199T3 (es) * 2012-09-28 2018-03-14 Kyowa Hakko Bio Co., Ltd. Agente para aumentar la inmunidad que contiene glutatión
RU2545900C2 (ru) * 2013-05-07 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Способ диагностики апоптоза лимфоцитов
RU2540500C2 (ru) * 2013-05-07 2015-02-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Способ прогнозирования ранней стадии апоптоза
RU2659161C1 (ru) 2017-11-17 2018-06-28 Общество С Ограниченной Ответственностью "Ива Фарм" Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид
CN114617899B (zh) * 2022-04-14 2023-10-20 苏州大学附属儿童医院 S-腺苷甲硫氨酸在制备治疗脓毒血症相关性脑病药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277619A (ja) * 1985-06-04 1986-12-08 Otsuka Pharmaceut Factory Inc 肝疾患治療剤
JP2921124B2 (ja) * 1990-12-28 1999-07-19 千寿製薬株式会社 酸化型グルタチオンアルキルエステル
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5618823A (en) * 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
GB9303854D0 (en) * 1993-02-25 1993-04-14 Holt John A G Method for enhancing t-cell count

Also Published As

Publication number Publication date
ES2174124T3 (es) 2002-11-01
ATE214936T1 (de) 2002-04-15
DE69620233D1 (de) 2002-05-02
EP0869809A1 (en) 1998-10-14
WO1997021444A1 (en) 1997-06-19
JP2000515111A (ja) 2000-11-14
EP0869809B1 (en) 2002-03-27
CA2239874A1 (en) 1997-06-19
JP2008001722A (ja) 2008-01-10
AU1113097A (en) 1997-07-03

Similar Documents

Publication Publication Date Title
EP0655460B1 (de) Pharmazeutisch therapeutische Verwendung von Glutathion-Derivaten
RU2089179C1 (ru) Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
DE69434121T2 (de) Pharmazeutische zusammensetzung zur immunverstärkenden therapie
EP1471902B1 (en) Compositions for use in methods for treating hearing loss
US5128126A (en) Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions
ES2312884T3 (es) Composiciones antivirales que comprenden derivados de acido fenilacetico.
EP0869809B1 (en) Oxidized glutathione as cytokine and hemopoietic factor endogenous production enhancer
US6063814A (en) Phorbol esters as anti-neoplastic and white blood cell elevating agents
US5684045A (en) Method of treating pancreatic atrophy
DE69026620T2 (de) Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor-agonisten
EP0774255B1 (en) Use of ursolic acid for the manufacture of a medicament for suppressing metastasis
DE69634074T2 (de) Thiole zur Förderung des Wachstums von Hömatopoietischen Vorläuferzellen
US5360790A (en) Method and formulations for the therapy of acute renal failure
WO1997021444A9 (en) Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
RU2153351C2 (ru) Средство для регулирования эндогенной продукции цитокинов и гемопоэтических факторов (варианты) и способ его использования
DE60222383T2 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
US6251857B1 (en) Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
EP0488718A2 (en) Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
DE3780770T2 (de) Therapeutisches gemisch aus einem faenger von freien radikalen oder einem stoffwechsel-hemmer und einem biologisch aktiven protein.
DE69124380T2 (de) Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten
KR0133555B1 (ko) 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
JP2002302447A (ja) 局所投与用癌治療剤
Blom-Muilwijk et al. Pulmonary toxicity after treatment with bleomycin alone or in combination with hyperoxia: studies in the rat
Thakur et al. Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis?
KR100514009B1 (ko) 1,2,4-벤조트리아진옥사이드제제

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN